Prostate Cancer News Archive

Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS

Prostate Cancer Pathologic Stage Alone Independently Predicts BCRFS

Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.

Testosterone Patterns Predict Prostate Cancer Risk

Testosterone Patterns Predict Prostate Cancer Risk

The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.

BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC

BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC

Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.

IMRT for Prostate Cancer Radiation Therapy Soars

IMRT for Prostate Cancer Radiation Therapy Soars

Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.

Prostate Cancer Risk Lower in NSAID Users

Prostate Cancer Risk Lower in NSAID Users

In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.

Prostate Cancer Active Surveillance Use Low, But Increasing

Prostate Cancer Active Surveillance Use Low, But Increasing

Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.

First Metastasis Site Predicts Prostate Cancer-Specific Survival

First Metastasis Site Predicts Prostate Cancer-Specific Survival

Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.

Additions to Standard Care in High-Risk PCa May Up Survival

Additions to Standard Care in High-Risk PCa May Up Survival

Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.

Proximal PSA Predicts Prostate Cancer Metastasis Risk

Proximal PSA Predicts Prostate Cancer Metastasis Risk

PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.

Toxicity Similar for 6- and 2- Fraction HDR Brachytherapy in PCa

Toxicity Similar for 6- and 2- Fraction HDR Brachytherapy in PCa

The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.

Prostate Cancer Screening Saves Lives, New Analysis Shows

Prostate Cancer Screening Saves Lives, New Analysis Shows

A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.

Prostate Cancer ADT Linked With Cardiovascular Risks, Depression

Prostate Cancer ADT Linked With Cardiovascular Risks, Depression

In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.

Urologist Ownership of IMRT Linked to Its Greater Use for PCa

Urologist Ownership of IMRT Linked to Its Greater Use for PCa

Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.

Short-term Arterial Thromboembolism Risk Elevated in Cancer Patients

Short-term Arterial Thromboembolism Risk Elevated in Cancer Patients

The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.

Cancer Patient Self-Reporting Reliable and Feasible, Studies Show

Cancer Patient Self-Reporting Reliable and Feasible, Studies Show

Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.

Osteoporosis Drugs Up Bone Mineral Density in Nonmetastatic PCa

Osteoporosis Drugs Up Bone Mineral Density in Nonmetastatic PCa

Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.

Not All High-Risk Prostate Cancers Are the Same

Not All High-Risk Prostate Cancers Are the Same

Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.

Blacks Less Likely to Undergo Definitive Prostate Cancer Therapy

Blacks Less Likely to Undergo Definitive Prostate Cancer Therapy

Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

Timing of PSA Nadir Post-RP Predicts Biochemical Recurrence Risk

A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.

Positive Lymph Node Prostate Cancer Care Patterns Characterized

Positive Lymph Node Prostate Cancer Care Patterns Characterized

63% of patients were managed initially with observation.

Active Surveillance for Intermediate-Risk PCa May Be Unsafe

Active Surveillance for Intermediate-Risk PCa May Be Unsafe

Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.

Top Complaint After Prostate Biopsy Is Infection

Top Complaint After Prostate Biopsy Is Infection

Most common infection in prostate biopsy was E. coli, followed by mild bleeding.

Vascular Targeted Photodynamic Tx Tied to Good Outcomes in Low-Risk PCa

Vascular Targeted Photodynamic Tx Tied to Good Outcomes in Low-Risk PCa

Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.

Vasectomy Poses Minimal Risk of Prostate Cancer

Vasectomy Poses Minimal Risk of Prostate Cancer

Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.

Active Surveillance for Intermediate-risk Prostate Cancer Challenged

Active Surveillance for Intermediate-risk Prostate Cancer Challenged

Study reveals that a quarter of men with low-volume intermediate-risk prostate cancer had adverse pathologic features found at radical prostatectomy.

Tall, Obese Men More Likely to Have Aggressive Prostate Cancer

Tall, Obese Men More Likely to Have Aggressive Prostate Cancer

Every additional 4 inches of height was associated with a 21% increase in risk of being diagnosed with high-grade prostate cancer, and a 17% increased risk of dying from prostate cancer.

RP for Prostate Cancer May Not Offer Survival Advantage

RP for Prostate Cancer May Not Offer Survival Advantage

Randomized trial found no significant difference in all-cause and cancer-specific survival between radical prostatectomy and observation for localized prostate cancer.

Decisional Regret Doesn't Vary by Tx in PCa

Decisional Regret Doesn't Vary by Tx in PCa

Across time, only African-American race correlated with greater regret.

Germline Mutations Up in PCa Patients With Another Primary Cancer

Germline Mutations Up in PCa Patients With Another Primary Cancer

Men with prostate cancer and at least one additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer-predisposing gene.

Radical Prostatectomy Use for High-Risk Prostate Cancer Rises Sharply

Radical Prostatectomy Use for High-Risk Prostate Cancer Rises Sharply

Over a 10-year period, radical prostatectomy use increased steadily while radiotherapy use declined

Prostate Atrophy, Inflammation Associated With Lower PCa Risk

Prostate Atrophy, Inflammation Associated With Lower PCa Risk

Both findings on biopsy also predict a lower odds of high-grade cancer.

Negative Confirmatory Biopsy a Good Sign in Prostate Cancer AS

Negative Confirmatory Biopsy a Good Sign in Prostate Cancer AS

Prostate cancer patients on active surveillance who have no cancer found on confirmatory biopsy have a reduced risk of grade and volume reclassification.

PSA Testing in Controls of Screening Trial May Undermine Results

PSA Testing in Controls of Screening Trial May Undermine Results

Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing

Novel Markers May Predict Prostate Cancer in Non-Black Men

Novel Markers May Predict Prostate Cancer in Non-Black Men

No added benefit was seen with the addition of biomarkers for African-American men.

Multimodal Therapy Found to Benefit Men With LN-positive PCa

Multimodal Therapy Found to Benefit Men With LN-positive PCa

New findings suggest that clinicians consider the pathologic characteristics of the primary tumor as well as the burden of LN metastases when deciding on management, investigators say.

Post-RP Radiotherapy Benefits Selected Men With Elevated PSA

Post-RP Radiotherapy Benefits Selected Men With Elevated PSA

Radiotherapy for prostate cancer patients with persistently elevated PSA after radical surgery improved survival only among those with worse pathologic characteristics.

High-income US Counties Have Higher Diagnoses of PCa

High-income US Counties Have Higher Diagnoses of PCa

High-income counties had far higher diagnosis rates for the four cancers than low-income counties, but the combined mortality rate was similar for both.

Survival Up With Patient-Reported Symptom Monitoring During Chemo

Survival Up With Patient-Reported Symptom Monitoring During Chemo

The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively.

Men Need Better Understanding of PCa Genetic Test Results

Men Need Better Understanding of PCa Genetic Test Results

Some men who undergo multigene testing for inherited prostate cancer misinterpret findings of variants of uncertain significance.

Surgery May Offer Better Survival for Younger Men With High-risk PCa

Surgery May Offer Better Survival for Younger Men With High-risk PCa

Younger patients who chose surgery vs radiation for initial treatment had a 48% survival advantage.

Extended PLND Not Associated With Short-Term Oncologic Benefits

Extended PLND Not Associated With Short-Term Oncologic Benefits

Extended pelvic lymph node dissection versus limited dissection during radical prostatectomy does not improve biochemical recurrence rates.

Chronic Prostatitis Has Adverse Effects on Sperm

Chronic Prostatitis Has Adverse Effects on Sperm

CBP was associated with a reduction in sperm concentration, sperm vitality, sperm total and progressive motility.

Single Radiation Dose Can Ease Spinal Cord Compression

Single Radiation Dose Can Ease Spinal Cord Compression

New findings establish single-dose radiotherapy as the standard of care for metastatic spinal canal compression, at least for patients with a short life expectancy, researcher says.

Survival Predictors ID'd in mCRPC Patients Treated With Sipuleucel-T

Survival Predictors ID'd in mCRPC Patients Treated With Sipuleucel-T

ECOG status and baseline PSA and PSADT are significantly associated with overall survival.

Low-PSA, High-Grade Prostate Cancer Especially Lethal

Low-PSA, High-Grade Prostate Cancer Especially Lethal

Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.

Costs Rise After Discovery of Prostate Cancer Metastases

Costs Rise After Discovery of Prostate Cancer Metastases

The researchers found that predicted monthly costs remained relatively stable throughout the observation period among the controls.

First-Line Abiraterone-ADT Combo for Hormone-Naïve PCa Ups Survival

First-Line Abiraterone-ADT Combo for Hormone-Naïve PCa Ups Survival

Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.

Abiraterone Plus ADT Ups Prostate Cancer Patient Survival

Abiraterone Plus ADT Ups Prostate Cancer Patient Survival

The 3-year overall survival rate among prostate cancer patients starting long-term hormone therapy was 83% vs 76% for men receiving abiraterone plus ADT vs ADT alone.

Diminished QOL Reported More Than 10 Years After PCa Treatment

Diminished QOL Reported More Than 10 Years After PCa Treatment

Urinary incontinence and diminished sexual function were common after a median follow-up of nearly 15 years, study finds.

Salvage RARP Feasible After PCa Focal Therapy Failure

Salvage RARP Feasible After PCa Focal Therapy Failure

Overall complication rates were similar between primary and salvage RARP groups, but there were some notable differences in prognosis.

MRI Accuracy for Prostate Cancer Challenged

MRI Accuracy for Prostate Cancer Challenged

Systematic biopsies always should be performed in conjunction with targeted biopsy in men with suspected clinically significant PCa at mpMRI.

Novel PSA Assay Improves Prostate Cancer Diagnosis

Novel PSA Assay Improves Prostate Cancer Diagnosis

The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.

Combined Urinary Testing Helps Detect Aggressive PCa, Avoid Biopsy

Combined Urinary Testing Helps Detect Aggressive PCa, Avoid Biopsy

Combining testing of urinary T2:ERG, PCA3 at thresholds that detected aggressive prostate cancer improved specificity from 18% to 39%.

Detection Down for Prostate Cancer, Up for Other Cancers Since ACA

Detection Down for Prostate Cancer, Up for Other Cancers Since ACA

The investigators found that the percentage of patients diagnosed with stage I cancer increased significantly from 2013 to 2014 after the ACA was implemented.

Prostate Cancer Subtypes Differ in ADT Response After Surgery

Prostate Cancer Subtypes Differ in ADT Response After Surgery

Only luminal B prostate cancers were significantly associated with postoperative response to ADT in a subset analysis in retrospective cohorts.

PCa Active Surveillance Safe, Effective for Younger Patients

PCa Active Surveillance Safe, Effective for Younger Patients

A majority of active surveillance patients under age 60 did not progress to definitive prostate cancer treatment.

MRI-Fusion Biopsy Benefits PCa Active Surveillance Patients

MRI-Fusion Biopsy Benefits PCa Active Surveillance Patients

Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer.

Sipuleucel-T Survival Benefit Greater in Blacks

Sipuleucel-T Survival Benefit Greater in Blacks

Median overall survival was 9.3 months longer for black versus white patients with metastatic castration-resistant prostate cancer.

Fusion Biopsy Ups Detection of Clinically Significant PCa

Fusion Biopsy Ups Detection of Clinically Significant PCa

Fusion biopsy has improved over the last decade and increasingly detects clinically significant prostate cancer, according to data trends from one institution.

Prostate Cancer Distant Metastasis Predicted by APV

Prostate Cancer Distant Metastasis Predicted by APV

Highest quartile of alkaline phosphatase velocity in men who experience biochemical recurrence after radical prostatectomy is associated with 2-fold higher risk.

Non-index Lesions at Biopsy Help Predict Adverse RP Outcomes

Non-index Lesions at Biopsy Help Predict Adverse RP Outcomes

Systematic biopsy parameters identified patients at higher risk of positive surgical margins.

HoLEP Feasible for BPH Patients With Low-risk Prostate Cancer

HoLEP Feasible for BPH Patients With Low-risk Prostate Cancer

The laser procedure was successful for 7 selected patients with enlarged prostates and LUTS harboring low-risk prostate cancer.

New Risk Models May Reduce Unnecessary Prostate Biopsies

New Risk Models May Reduce Unnecessary Prostate Biopsies

The new risk models improve upon PI-RADS version 1.0 and ERPSC risk calculators used for prostate biopsy decisions.

New Nomogram Improves Post-RP Metastasis Predictions

New Nomogram Improves Post-RP Metastasis Predictions

Nomogram based on a cohort of men with high-risk prostate cancer is more accurate than the CAPRA and MSKCC nomograms, researchers report.

Cholesterol Linked to High-Grade Prostate Cancer

Cholesterol Linked to High-Grade Prostate Cancer

Each 10 mg/dL increase in total cholesterol is associated with a significant 23% greater odds of high-grade prostate cancer.

Bone Metastasis at Diagnosis Predicts Early Prostate Cancer Mortality

Bone Metastasis at Diagnosis Predicts Early Prostate Cancer Mortality

Men who present with prostate cancer bone metastasis and no visceral metastases have a median survival time of 37 months, study finds.

Biopsy Timing in Active Surveillance Not Tied to PCa Reclassification

Biopsy Timing in Active Surveillance Not Tied to PCa Reclassification

But PSA density and body mass index are associated with prostate cancer reclassification.

Yoga May Relieve Symptoms of Prostate Cancer Radiation Tx

Yoga May Relieve Symptoms of Prostate Cancer Radiation Tx

Men who attended yoga classes had less fatigue and better sexual and urinary function than those in the comparison group.

PSA Surge With Abiraterone Has No Long-Term Impact on Outcome

PSA Surge With Abiraterone Has No Long-Term Impact on Outcome

Spike in PSA level after starting abiraterone does not affect progression-free or overall survival, study finds.

More Preclinical PCa, Progression Among Black Men

More Preclinical PCa, Progression Among Black Men

Also increased risk of progression to metastatic disease compared with the general population.

Metformin Plus Chemo Does Not Up mCRPC Survival

Metformin Plus Chemo Does Not Up mCRPC Survival

Survival curves showed that metformin use with docetaxel did not improve prostate cancer specific survival or overall survival.

USPSTF Issues Draft PCa Screening Recommendations

USPSTF Issues Draft PCa Screening Recommendations

The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.

PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC

PSA Doubling Time Predicts Metastasis, Mortality Risks in CRPC

Study identifies PSADT cut-points that can aid in risk stratification of men with non-metastatic castration-resistant prostate cancer.

Prostate Cancer Risk Lower in Black Men With High VDBP

Prostate Cancer Risk Lower in Black Men With High VDBP

Highest vs lowest quartile of vitamin D binding protein associated with 55% lower odds of prostate cancer.

Prostate Cancer Progression Risk in AS Not Linked to Family History

Prostate Cancer Progression Risk in AS Not Linked to Family History

A family history of prostate cancer was not a major determinant of disease progression during active surveillance, according to a systematic review.

Taking Aspirin Regularly May Reduce Death From Cancer

Taking Aspirin Regularly May Reduce Death From Cancer

Regular aspirin use linked to lower risk of cancer mortality, especially colorectal, breast, and prostate cancer.

Earlier vs Later Prostate Cancer Recurrence Characterized

Earlier vs Later Prostate Cancer Recurrence Characterized

Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.

Lack of Sleep Linked to Prostate Cancer Death in Younger Men

Lack of Sleep Linked to Prostate Cancer Death in Younger Men

Among men under the age of 65, men who got 3 to 5 hours of sleep per night had a 55% greater risk of dying of prostate cancer than men who got 7 hours of sleep per night.

Predictors of Post-RARP Readmission Identified

Predictors of Post-RARP Readmission Identified

Patients with longer hospital stays and pre-discharge complications were at increased risk of readmission within 30 days of discharge.

Many Men Lack Information on PSA Screening Pros, Cons

Many Men Lack Information on PSA Screening Pros, Cons

In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.

Study Supports PCa Screening With MRI vs TRUS-biopsy

Study Supports PCa Screening With MRI vs TRUS-biopsy

Population-based prostate cancer screening with MRI has a significantly better risk/benefit ratio.

Study Finds Low Rate of AS Failure Regardless of PCa Risk

Study Finds Low Rate of AS Failure Regardless of PCa Risk

Select intermediate- and high-risk patients had no greater risks of metastases, AS failure, or interventions over a median of 4 years.

Prostate Cancer Active Surveillance Does Not Up Metastasis Risk

Prostate Cancer Active Surveillance Does Not Up Metastasis Risk

Study finds no difference in metastasis-free survival observed after 15 years compared with radiation therapy or radical prostatectomy.

Prostate Biopsy May Be Avoidable if MRI Findings Are Negative

Prostate Biopsy May Be Avoidable if MRI Findings Are Negative

In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.

Adverse Effects of Treatment for Localized PCa Clarified

Adverse Effects of Treatment for Localized PCa Clarified

Findings from 2 new studies could enable more informed patient counseling about choice of therapy.

Nerve-sparing RP May Not Raise Positive Margin Risk

Nerve-sparing RP May Not Raise Positive Margin Risk

Researchers found no evidence of worse cancer outcomes with nerve-sparing surgery.

TRT Does Not Appear to Increase PCa Risk

TRT Does Not Appear to Increase PCa Risk

A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).

Bone Metastases Seldom Progress During Radium-223 Therapy

Bone Metastases Seldom Progress During Radium-223 Therapy

At 6 months of treatment, bone imaging showed stable disease in 94% of patients with available data, study finds.

Prostate MRI Quality May Improve With Bowel Prep

Prostate MRI Quality May Improve With Bowel Prep

In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.

Targeted Biopsy Detects Gleason Score Upgrading in AS

Targeted Biopsy Detects Gleason Score Upgrading in AS

Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

PFS Longer With Abiraterone As Second-Line mCRPC Treatment

Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

PSA, PSAD Less Predictive of Aggressive PCa in Black Men

Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.

Researchers Identify mCRPC Drug Sequence Offering the Best Survival

Researchers Identify mCRPC Drug Sequence Offering the Best Survival

In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.

Urologists Support Targeted Biopsy

Urologists Support Targeted Biopsy

In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

5-Year PCa-Specific Mortality Declined With Increased PSA Testing

From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.

Prostate Cancer Treatment Prolongs Survival

Prostate Cancer Treatment Prolongs Survival

Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.

Higher BMI Lowers Death Risk in Men With Advanced Prostate Cancer

Higher BMI Lowers Death Risk in Men With Advanced Prostate Cancer

In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.

Black Patients May Be Adversely Affected by Less PSA Screening

Black Patients May Be Adversely Affected by Less PSA Screening

Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.

Metastatic Prostate Cancer Death Rates Declining

Metastatic Prostate Cancer Death Rates Declining

Cancer-specific mortality rates dropped from 72.8% in 1995 to 55.8% in 2011, according to a Danish study.

Prostate Cancer Risk Stratification Enhanced by Novel MRI Protocol

Prostate Cancer Risk Stratification Enhanced by Novel MRI Protocol

Researchers compared targeted prostate biopsy based on biparametric magnetic resonance imaging with standard 12-core systematic biopsy.

Sign Up for Free e-newsletters